TOKYO — A new study offers a more personal look at breast cancer, suggesting that the way cells stick together could help doctors choose the right treatment for each patient. Researchers have identified specific gene signatures tied to cell-cell junctions—the biological “glue” that holds cells together—that behave differently depending on the type of breast cancer. For communities across Asia, where breast cancer rates are rising, this could mean more targeted therapies and fewer harsh side effects.
The study, published in PLOS One and led by a team of researchers, examined data from breast cancer patients. They found that the expression of genes related to cell-cell junctions was not uniform across all breast cancer subtypes.
In some aggressive forms, these junction genes were suppressed, potentially allowing cancer cells to break away and spread more easily. “Cell-cell junction gene signatures are not just markers of tumour structure,” the researchers noted in their paper. “They can serve as subtype-specific prognostic biomarkers that reflect the underlying biology of the disease.” What it means for people, closer to home, is that a simple genetic test on a tumour biopsy could one day tell a doctor whether a patient’s cancer is likely to be slow-growing or aggressive.
This could spare some women from unnecessary chemotherapy while guiding others toward more intensive treatment early on. The team identified distinct patterns in luminal, HER2-enriched, and triple-negative breast cancers.
For families in the region, where access to advanced diagnostics can be uneven, these findings could eventually lead to simpler, more affordable tests that work across different healthcare settings. The study’s authors emphasised that their work is still at the discovery stage. Clinical trials would be needed before these gene signatures become part of routine care.
But for now, the research offers a clearer roadmap for understanding why some breast cancers respond to treatment and others do not. Looking ahead, the next step is to validate these gene signatures in larger, more diverse patient populations—including women from Asian countries, who are often underrepresented in such studies. Consult your doctor for medical advice.
